The science of adjuvants

References

• Hilleman MR. Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine18(15), 1436–1447 (2000).
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Valley U, Rappuoli R. Vaccine manufacturing: challenges and solutions. Nat. Biotechnol.24(11), 1377–1383 (2006).
   PubMed Web of Science ®Google Scholar
• Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature298(5872), 347–350 (1982).
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature388(6640), 394–397 (1997).
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Janeway CA Jr. Self-defense: the fruit fly style. Proc. Natl Acad. Sci. USA95(2), 429–430 (1998).
   PubMedGoogle Scholar
• Poltorak A, He X, Smirnova I et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in TLR4 gene. Science282(5396), 2085–2088 (1998).
   PubMed Web of Science ®Google Scholar
• Poltorak A, Ricciardi-Castagnoli P, Citterio S, Beutler B. Physical contact between lipopolysaccharide and Toll-like receptor 4 revealed by genetic complementation. Proc. Natl Acad. Sci. USA97(5), 2163–2167 (2000).
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell124(4), 783–801 (2006).
   PubMed Web of Science ®Google Scholar
• Kaisho T, Akira S. Toll-like receptor function and signaling. J. Allergy Clin. Immunol.117(5), 979–988 (2006).
   PubMed Web of Science ®Google Scholar
• Hornung V, Ellegast J, Kim S et al. 5´-triphosphate RNA is the ligand for RIG-I. Science314(5801), 994–997 (2006).
   PubMed Web of Science ®Google Scholar
• Ishii KJ, Akira S. Toll or Toll-free adjuvant path toward the optimal vaccine development. J. Clin. Immunol.27(4), 363–371 (2007).
   PubMed Web of Science ®Google Scholar
• Kato H, Takeuchi O, Sato S et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature441(7089), 101–105 (2006).
   PubMed Web of Science ®Google Scholar
• Martinon F, Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol.26(8), 447–454 (2005).
   PubMed Web of Science ®Google Scholar
• Robinson MJ, Sancho D, Slack EC, LeibundGut-Landmann S, Reis e Sousa C. Myeloid C-type lectins in innate immunity. Nat. Immunol.7(12), 1258–1265 (2006).
   PubMed Web of Science ®Google Scholar
• Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev.7(3), 179–190 (2007).
   Google Scholar
• Abreu MT, Fukata M, Arditi M. TLR signaling in the gut in health and disease. J. Immunol.174(8), 4453–4460 (2005).
   PubMed Web of Science ®Google Scholar
• Rimoldi M, Chieppa M, Salucci V et al. Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat. Immunol.6(5), 507–514 (2005).
   PubMed Web of Science ®Google Scholar
• Zaph C, Troy AE, Taylor BC et al. Epithelial-cell-intrinsic IKK-β expression regulates intestinal immune homeostasis. Nature446(7135), 552–556 (2007).
   PubMed Web of Science ®Google Scholar
• Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med.137(5), 1142–1162 (1973).
   PubMed Web of Science ®Google Scholar
• Steinman RM. Linking innate to adaptive immunity through dendritic cells. Novartis Found. Symp.279, 101–113, 216–109 (2006).
   PubMedGoogle Scholar
• Pulendran B, Smith JL, Caspary G et al. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. Natl Acad. Sci. USA96(3), 1036–1041 (1999).
   PubMed Web of Science ®Google Scholar
• den Haan JM, Lehar SM, Bevan MJ. CD8+ but not CD8- dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med.192(12), 1685–1696 (2000).
   PubMed Web of Science ®Google Scholar
• Dillon S, Agrawal A, Van Dyke T et al. A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J. Immunol.172(8), 4733–4743 (2004).
   PubMed Web of Science ®Google Scholar
• Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nat. Rev.7(1), 19–30 (2007).
   Google Scholar
• Kadowaki N, Antonenko S, Lau JY, Liu YJ. Natural interferon α/β-producing cells link innate and adaptive immunity. J. Exp. Med.192(2), 219–226 (2000).
   PubMed Web of Science ®Google Scholar
• Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell124(4), 849–863 (2006).
   PubMed Web of Science ®Google Scholar
• Gavin AL, Hoebe K, Duong B et al. Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science314(5807), 1936–1938 (2006).
   PubMed Web of Science ®Google Scholar
• Martin M, Michalek SM, Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect. Immun.71(5), 2498–2507 (2003).
   PubMed Web of Science ®Google Scholar
• Hayashi F, Smith KD, Ozinsky A et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature410(6832), 1099–1103 (2001).
   PubMed Web of Science ®Google Scholar
• Yarovinsky F, Zhang D, Andersen JF et al. TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science308(5728), 1626–1629 (2005).
   PubMed Web of Science ®Google Scholar
• McCluskie MJ, Krieg AM. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr. Top. Microbiol. Immunol.311, 155–178 (2006).
   PubMed Web of Science ®Google Scholar
• Heil F, Hemmi H, Hochrein H et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science303(5663), 1526–1529 (2004).
   PubMed Web of Science ®Google Scholar
• Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov.5(6), 471–484 (2006).
   PubMed Web of Science ®Google Scholar
• Honda K, Ohba Y, Yanai H et al. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature434(7036), 1035–1040 (2005).
   PubMed Web of Science ®Google Scholar
• Redecke V, Hacker H, Datta SK et al. Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J. Immunol.172(5), 2739–2743 (2004).
   PubMed Web of Science ®Google Scholar
• Pulendran B, Kumar P, Cutler CW, Mohamadzadeh M, Van Dyke T, Banchereau J. Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. J. Immunol.167(9), 5067–5076 (2001).
   PubMed Web of Science ®Google Scholar
• Agrawal A, Lingappa J, Leppla SH et al. Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature424(6946), 329–334 (2003).
   PubMed Web of Science ®Google Scholar
• Dillon S, Agrawal S, Banerjee K et al. Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J. Clin. Invest.116(4), 916–928 (2006).
   PubMed Web of Science ®Google Scholar
• Cetron MS, Marfin AA, Julian KG et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm. Rep.51(RR-17), 1–14 (2002).
   PubMedGoogle Scholar
• Datta SK, Redecke V, Prilliman KR et al. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J. Immunol.170(8), 4102–4110 (2003).
   PubMed Web of Science ®Google Scholar
• Cooper CL, Davis HL, Angel JB et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS19(14), 1473–1479 (2005).
   PubMed Web of Science ®Google Scholar
• Payette PJ, Ma X, Weeratna RD et al. Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge. Intervirology49(3), 144–151 (2006).
   PubMedGoogle Scholar
• Pasare C, Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature438(7066), 364–368 (2005).
   PubMed Web of Science ®Google Scholar
• Bergman MP, Engering A, Smits HH et al. Helicobacter pylori modulates the T helper cell 1/T helper cell 2 balance through phase-variable interaction between lipopolysaccharide and DC-SIGN. J. Exp. Med.200(8), 979–990 (2004).
   PubMed Web of Science ®Google Scholar
• LeibundGut-Landmann S, Gross O, Robinson MJ et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat. Immunol.8(6), 630–638 (2007).
   PubMed Web of Science ®Google Scholar
• Caparros E, Munoz P, Sierra-Filardi E et al. DC-SIGN ligation on dendritic cells results in ERK and PI3K activation and modulates cytokine production. Blood107(10), 3950–3958 (2006).
   PubMed Web of Science ®Google Scholar
• Wieland CW, Koppel EA, den Dunnen J et al. Mice lacking SIGNR1 have stronger T helper 1 responses to Mycobacterium tuberculosis. Microbes Infect.9(2), 134–141 (2007).
   PubMedGoogle Scholar
• Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature442(7098), 39–44 (2006).
   PubMed Web of Science ®Google Scholar
• Fritz JH, Ferrero RL, Philpott DJ, Girardin SE. NOD-like proteins in immunity, inflammation and disease. Nat. Immunol.7(12), 1250–1257 (2006).
   PubMed Web of Science ®Google Scholar
• Inohara N, Nunez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat. Rev.3(5), 371–382 (2003).
   Google Scholar
• Kobayashi K, Inohara N, Hernandez LD et al. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature416(6877), 194–199 (2002).
   PubMed Web of Science ®Google Scholar
• Martinon F, Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell117(5), 561–574 (2004).
   PubMed Web of Science ®Google Scholar
• Schmitz J, Owyang A, Oldham E et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity23(5), 479–490 (2005).
   PubMed Web of Science ®Google Scholar
• Allison AC, Byars NE. Immunological adjuvants: desirable properties and side-effects. Mol. Immunol.28(3), 279–284 (1991).
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kitani A, Murray PJ, Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat. Immunol.5(8), 800–808 (2004).
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kitani A, Murray PJ, Wakatsuki Y, Fuss IJ, Strober W. Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis. Immunity25(3), 473–485 (2006).
   PubMed Web of Science ®Google Scholar
• Maeda S, Hsu LC, Liu H et al. NOD2 mutation in Crohn’s disease potentiates NF-κB activity and IL-1β processing. Science307(5710), 734–738 (2005).
   PubMed Web of Science ®Google Scholar
• Fritz JH, Le Bourhis L, Sellge G et al. NOD1-mediated innate immune recognition of peptidoglycan contributes to the onset of adaptive immunity. Immunity26(4), 445–459 (2007).
   PubMed Web of Science ®Google Scholar
• Molofsky AB, Byrne BG, Whitfield NN et al. Cytosolic recognition of flagellin by mouse macrophages restricts Legionella pneumophila infection. J. Exp. Med.203(4), 1093–1104 (2006).
   PubMed Web of Science ®Google Scholar
• Ren T, Zamboni DS, Roy CR, Dietrich WF, Vance RE. Flagellin-deficient Legionella mutants evade caspase-1- and Naip5-mediated macrophage immunity. PLoS Pathog.2(3), e18 (2006).
   PubMed Web of Science ®Google Scholar
• Kawai T, Takahashi K, Sato S et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol.6(10), 981–988 (2005).
   PubMed Web of Science ®Google Scholar
• Pichlmair A, Schulz O, Tan CP et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5´-phosphates. Science314(5801), 997–1001 (2006).
   PubMed Web of Science ®Google Scholar
• Yoneyama M, Fujita T. Function of RIG-I-like receptors in antiviral innate immunity. J. Biol. Chem.282(21), 15315–15318 (2007).
   PubMed Web of Science ®Google Scholar
• Saito T, Hirai R, Loo YM et al. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc. Natl. Acad. Sci. USA104(2), 582–587 (2007).
   PubMed Web of Science ®Google Scholar
• Saito T, Gale M Jr. Principles of intracellular viral recognition. Curr. Opin. Immunol.19(1), 17–23 (2007).
   PubMed Web of Science ®Google Scholar
• Takaoka A, Wang Z, Choi MK et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature448(7152), 501–505 (2007).
   PubMed Web of Science ®Google Scholar
• Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol.6(8), 769–776 (2005).
   PubMed Web of Science ®Google Scholar
• Henderson DA. The challenge of eradication: lessons from past eradication campaigns. Int. J. Tuberc. Lung Dis.2(9 Suppl. 1), S4–S8 (1998).
   PubMed Web of Science ®Google Scholar
• Monath TP. Yellow fever vaccine. Expert Rev. Vaccines4(4), 553–574 (2005).
   PubMed Web of Science ®Google Scholar
• Hawgood BJ. Albert Calmette (1863–1933) and Camille Guerin (1872–1961): the C and G of BCG vaccine. J. Med. Biogr.15(3), 139–146 (2007).
   PubMedGoogle Scholar
• Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K. Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine. Bull. World Health Organ.59(6), 895–900 (1981).
   Google Scholar
• Querec T, Bennouna S, Alkan S et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med.203(2), 413–424 (2006).
   PubMed Web of Science ®Google Scholar
• Fenner F. The global eradication of smallpox. Med. J. Aust.1(10), 455–455 (1980).
   PubMedGoogle Scholar
• Harte MT, Haga IR, Maloney G et al. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J. Exp. Med.197(3), 343–351 (2003).
   PubMed Web of Science ®Google Scholar
• Maloney G, Schroder M, Bowie AG. Vaccinia virus protein A52R activates p38 mitogen-activated protein kinase and potentiates lipopolysaccharide-induced interleukin-10. J. Biol. Chem.280(35), 30838–30844 (2005).
   PubMed Web of Science ®Google Scholar
• Stack J, Haga IR, Schroder M et al. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J. Exp. Med.201(6), 1007–1018 (2005).
   PubMed Web of Science ®Google Scholar
• Geijtenbeek TB, Van Vliet SJ, Koppel EA et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J. Exp. Med.197(1), 7–17 (2003).
   PubMed Web of Science ®Google Scholar
• Tsuji S, Matsumoto M, Takeuchi O et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette–Guerin: involvement of Toll-like receptors. Infect. Immun.68(12), 6883–6890 (2000).
   PubMed Web of Science ®Google Scholar
• von Meyenn F, Schaefer M, Weighardt H et al. Toll-like receptor 9 contributes to recognition of Mycobacterium bovis bacillus Calmette-Guerin by Flt3-ligand generated dendritic cells. Immunobiology211(6–8), 557–565 (2006).
   PubMedGoogle Scholar
• O’Hagan DT, Valiante NM. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov.2(9), 727–735 (2003).
   PubMed Web of Science ®Google Scholar
• Glenn GM, Villar CP, Flyer DC et al. Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum. Infect. Immun.75(5), 2163–2170 (2007).
   PubMed Web of Science ®Google Scholar
• McKenzie R, Bourgeois AL, Frech SA et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine25(18), 3684–3691 (2007).
   PubMed Web of Science ®Google Scholar
• Li H, Nookala S, Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1β and IL-18 release. J. Immunol.178(8), 5271–5276 (2007).
   PubMed Web of Science ®Google Scholar
• Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev. Vaccines2(2), 197–203 (2003).
   PubMedGoogle Scholar
• Dupuis M, Murphy TJ, Higgins D et al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell. Immunol.186(1), 18–27 (1998).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Ott GS, Van Nest G. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Mol. Med. Today3(2), 69–75 (1997).
   PubMedGoogle Scholar
• Valensi JP, Carlson JR, Van Nest GA. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J. Immunol.153(9), 4029–4039 (1994).
   PubMed Web of Science ®Google Scholar
• Alderson MR, McGowan P, Baldridge JR, Probst P. TLR4 agonists as immunomodulatory agents. J. Endotoxin Res.12(5), 313–319 (2006).
   PubMedGoogle Scholar
• Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med.13(5), 552–559 (2007).
   PubMed Web of Science ®Google Scholar
• Dupont J, Altclas J, Lepetic A et al. A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine. Vaccine24(49–50), 7167–7174 (2006).
   PubMed Web of Science ®Google Scholar
• Giannini SL, Hanon E, Moris P et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine24(33–34), 5937–5949 (2006).
   PubMed Web of Science ®Google Scholar
• Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science316(5831), 1628–1632 (2007).
   PubMed Web of Science ®Google Scholar
• Krieg AM. Development of TLR9 agonists for cancer therapy. J. Clin. Invest.117(5), 1184–1194 (2007).
   PubMed Web of Science ®Google Scholar
• Heit A, Schmitz F, O'Keeffe M et al. Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines. J. Immunol.174(7), 4373–4380 (2007).
   Google Scholar
• Heit A, Schmitz F, Haas T, Busch DH, Wagner H. Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity. Eur. J. Immunol.37(8), 2063–2074 (2007).
   PubMed Web of Science ®Google Scholar
• Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med.11(4 Suppl.), S63–S68 (2005).
   PubMed Web of Science ®Google Scholar
• Gaspari AA. Mechanism of action and other potential roles of an immune response modifier. Cutis79(Suppl. 4), 36–45 (2007).
   PubMed Web of Science ®Google Scholar
• Wille-Reece U, Flynn BJ, Lore K et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc. Natl Acad. Sci. USA102(42), 15190–15194 (2005).
   PubMed Web of Science ®Google Scholar
• Wille-Reece U, Flynn BJ, Lore K et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. Exp. Med.203(5), 1249–1258 (2006).
   PubMed Web of Science ®Google Scholar
• Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J. Immunol.174(12), 7676–7683 (2005).
   PubMed Web of Science ®Google Scholar
• Huleatt JW, Jacobs AR, Tang J et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine25(4), 763–775 (2007).
   PubMed Web of Science ®Google Scholar
• McDonald WF, Huleatt JW, Foellmer HG et al. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J. Infect. Dis.195(11), 1607–1617 (2007).
   PubMed Web of Science ®Google Scholar
• Franchi L, Amer A, Body-Malapel M et al. Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1β in salmonella-infected macrophages. Nat. Immunol.7(6), 576–582 (2006).
   PubMed Web of Science ®Google Scholar
• Miao EA, Alpuche-Aranda CM, Dors M et al. Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1β via Ipaf. Nat. Immunol.7(6), 569–575 (2006).
   PubMed Web of Science ®Google Scholar
• Spies B, Hochrein H, Vabulas M et al. Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J. Immunol.171(11), 5908–5912 (2003).
   PubMed Web of Science ®Google Scholar
• Pavlenko M, Leder C, Moreno S, Levitsky V, Pisa P. Priming of CD8+ T-cell responses after DNA immunization is impaired in TLR9- and MyD88-deficient mice. Vaccine25(34), 6341–6347 (2007).
   PubMed Web of Science ®Google Scholar
• Takeshita F, Tanaka T, Matsuda T et al. Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity. J. Virol.80(13), 6218–6224 (2006).
   PubMed Web of Science ®Google Scholar
• Chen YS, Hsiao YS, Lin HH, Liu Y, Chen YL. CpG-modified plasmid DNA encoding flagellin improves immunogenicity and provides protection against Burkholderia pseudomallei infection in BALB/c mice. Infect. Immun.74(3), 1699–1705 (2006).
   PubMed Web of Science ®Google Scholar
• Smorlesi A, Papalini F, Orlando F, Donnini A, Re F, Provinciali M. Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma. Gene Ther.12(17), 1324–1332 (2005).
   PubMed Web of Science ®Google Scholar
• Otero M, Calarota SA, Felber B et al. Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine22(13–14), 1782–1790 (2004).
   PubMed Web of Science ®Google Scholar
• Kwissa M, Amara RR, Robinson HL et al. Adjuvanting a DNA vaccine with TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus. J. Exp. Med. (2007) (in press).
   PubMedGoogle Scholar